close 73% inwestorów detalicznych traci pieniądze podczas handlu CFD z tym dostawcą. Inwestowanie wiąże się z ryzykiem i nie jest odpowiednie dla wszystkich inwestorów. Kontrakty CFD są złożonymi instrumentami i wiążą się z dużym ryzykiem szybkiej utraty środków pieniężnych z powodu dźwigni finansowej. 73% rachunków inwestorów detalicznych notuje stratę pieniędzy podczas handlu kontraktami CFD z tym dostawcą. Upewnij się, czy rozumiesz, jak działają kontrakty CFD, i czy możesz pozwolić sobie na wysokie ryzyko utraty pieniędzy.
Change languagePolski
Pulpit

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

LLY

1,036.37

-0.35%↓

JNJ

243.49

+0.08%↑

ABBV

232.69

+0.55%↑

NVS

166.17

+2.06%↑

MRK

121.6

+0.22%↑

Strona główna・Stock List・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Closed

SectorHealthcare

9.08 8.74

Strong Buy

Price update 17 lut 2026, 20:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

8.18

Max

9.91

Key metrics

By Trading Economics

Income

4.1M

-33M

Sales

6.1M

44M

EPS

-3.82

Profit margin

-75.213

Employees

279

EBITDA

1.8M

-23M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+94.29% upside

Market Stats

By TradingEconomics

Market Cap

13M

116M

Previous open

0.34

Previous close

9.08

News Sentiment

By Acuity

18%

82%

35 / 351 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.9501 / 7.66 Support & Resistance

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 lut 2026, 23:44 UTC

Hot Stocks

Stocks to Watch: La-Z-Boy, Palo Alto Networks, Caesars

DJ

Read

17 lut 2026, 23:20 UTC

Earnings

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps -- Update

DJ

Read

17 lut 2026, 22:57 UTC

Earnings

Santos Fiscal Year Net Profit Falls 33%, Nears Start of Alaska Project

DJ

Read

17 lut 2026, 21:59 UTC

Earnings

Palo Alto Networks Lifts FY26 Revenue Outlook as 2Q Profit Jumps

DJ

Read

17 lut 2026, 23:54 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Ease -- Market Talk

DJ

Read

17 lut 2026, 23:54 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Read

17 lut 2026, 23:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Read

17 lut 2026, 23:45 UTC

Market Talk

Suncorp's Outperformance of IAG Could Be Hard to Sustain -- Market Talk

DJ

Read

17 lut 2026, 23:19 UTC

Earnings

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

DJ

Read

17 lut 2026, 23:15 UTC

Earnings

Palo Alto's Guidance Overshadows Strong Earnings. Its Stock Is Down. -- Barrons.com

DJ

Read

17 lut 2026, 22:58 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Netflix Would Operate Warner's Studios, HBO Largely the Same -- Market Talk

DJ

Read

17 lut 2026, 22:58 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel: Board Committed to Optimizing Value For Shareholders

DJ

Read

17 lut 2026, 22:57 UTC

Acquisitions, Mergers, Takeovers

BlueScope Steel to Consider Revised SGH, Steel Dynamics Takeover Bid

DJ

Read

17 lut 2026, 22:50 UTC

Acquisitions, Mergers, Takeovers

Agnico-Eagle Mines Acquired 662,780 Common Shrs of Maple Gold Mines at C$2.45 Per Common Shr >AEM.T

DJ

Read

17 lut 2026, 22:44 UTC

Earnings

Palo Alto Reports Strong Earnings. Its Stock Is Down. -- Barrons.com

DJ

Read

17 lut 2026, 22:42 UTC

Earnings

Santos FY Net Profit Falls 33%, Nears Start of Alaska Project

DJ

Read

17 lut 2026, 22:36 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Netflix Sarandos: Paramount Causing Confusion Around Warner Deal -- Market Talk

DJ

Read

17 lut 2026, 22:36 UTC

Earnings

Santos Final Dividend 10.3 U.S. Cents/Security

DJ

Read

17 lut 2026, 22:36 UTC

Earnings

Santos FY Underlying Profit US$898 Million, Down 25%

DJ

Read

17 lut 2026, 22:35 UTC

Earnings

Santos FY Revenue US$4.94 Billion, Down 8%

DJ

Read

17 lut 2026, 22:35 UTC

Earnings

Correct: Santos FY Net Profit US$818 Million, Down 33%

DJ

Read

17 lut 2026, 22:35 UTC

Acquisitions, Mergers, Takeovers

Berkshire Buys New York Times Stock; Sells Apple, Bank of America, Amazon In 4Q -- Barrons.com

DJ

Read

17 lut 2026, 22:34 UTC

Earnings

Santos FY Net Profit US$818 Billion, Down 33%

DJ

Read

17 lut 2026, 22:02 UTC

Acquisitions, Mergers, Takeovers

Berkshire Pares Stakes in Apple and BofA, Adds New York Times Position -- Update

DJ

Read

17 lut 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics: SGH Would Buy BlueScope, On-sell North American Operations to SDI, As Earlier Proposed

DJ

Read

17 lut 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

DJ

Read

17 lut 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

DJ

Read

17 lut 2026, 21:49 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics Says Revised Proposal Continues to Present Highly Strategic Opportunity For SDI Shareholders

DJ

Read

17 lut 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics: BlueScope Offer a 56% Premium to 52-Week Volume Weighted Average Price

DJ

Read

17 lut 2026, 21:48 UTC

Acquisitions, Mergers, Takeovers

Steel Dynamics: Consideration To Be Comprised Entirely of Cash

DJ

Read

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

94.29% upside

12 Months Forecast

Average 16.67 USD  94.29%

High 23 USD

Low 12 USD

Based on 4 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Based on 4 analysts giving stock ratings to Karyopharm Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Strong Bearish Evidence

All events are bearish.

Long Term

No Evidence

There are no events.

Sentiment

By Acuity

35 / 351 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

Other stocks from the sector

LLY

Eli Lilly and Co.

1,036.37

↓-0.35%

JNJ

Johnson and Johnson

243.49

↑ +0.08%

ABBV

AbbVie Inc

232.69

↑ +0.55%

NVS

Novartis AG

166.17

↑ +2.06%

MRK

Merck & Co Inc.

121.6

↑ +0.22%
help-icon Live chat